Bivalirudin inhibits periprocedural platelet function and tissue factor expression of human smooth muscle cells
Cardiovascular Therapeutics, 04/26/2012Pepke W et al.
Bivalirudin is better than unfractionated heparin (UFH) in reducing periprocedural platelet activation. Moreover, thrombin–induced tissue factor (TF) expression is inhibited by bivalirudin. Thus, bivalirudin seems to be a better anticoagulant during percutaneous coronary intervention (PCI) than UFH.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.